Synthetic Biologics is developing biologics for preventing and treating serious infectious diseases. The company is developing an oral enzyme to prevent infections from Clostridium difficile, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon, and monoclonal antibody therapies for the treatment of whooping cough and other infections. The company is also developing a drug candidate for treating relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, visit the company’s website at www.syntheticbiologics.com.